Name: Latest research reports of Lupin Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Lupin Ltd.

NSE: LUPIN | BSE: 500257 | ISIN: INE326A01037 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

2357.8000 17.80 (0.76%)

NSE Jun 23, 2026 15:31 PM

28.36% Gain from 52W Low

Volume: 830.8K

Lupin Ltd.

15 Feb 2026

2357.80

0.76%

Lupin (BUY): Multiple growth levers for multiple years

Buy: Lupin Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA /APAT reported 8.2%/13.1%/25% above our estimates. EBITDA Margin reported 130 bps above our estimates

Lupin Ltd. is trading above all available SMAs